Skip to main content
Top

2009 | OriginalPaper | Hoofdstuk

21 Hepatitis

Auteur : Dr. E.H. van de Lisdonk

Gepubliceerd in: Praktische preventie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Hepatitis is een verzamelnaam voor diverse vormen van leverontsteking.[1,2,3] De etiologie van hepatitis is gevarieerd: virale infecties, infecties met andere micro-organismen zoals leptospirose, alcohol, obstructie van de galafvoer, toxische hepatitis zoals ten gevolge van geneesmiddelen, niet-alcoholische steatohepatitis.
Literatuur
1.
go back to reference Rubin RE, Strayer DS, Farber L, editors. Rubin’s Pathology. 5th ed. Philadelphia: Lippincott-Raven Williams & Wilkins, 2005. Rubin RE, Strayer DS, Farber L, editors. Rubin’s Pathology. 5th ed. Philadelphia: Lippincott-Raven Williams & Wilkins, 2005.
2.
go back to reference Kumar P, Clark M, editors. Clinical Medicin. 6e dr. London: Elsevier, 2005. Kumar P, Clark M, editors. Clinical Medicin. 6e dr. London: Elsevier, 2005.
3.
go back to reference Geldrop W van, Numans ME, Berg HF, et al. NHG-Standaard Virushepatitis en andere leveraandoeningen. Huisarts Wet 2007;50:666–8. Geldrop W van, Numans ME, Berg HF, et al. NHG-Standaard Virushepatitis en andere leveraandoeningen. Huisarts Wet 2007;50:666–8.
4.
go back to reference RIVM. Melden van infectieziekten conform de wet publieke gezondheid. Bilthoven: RIVM, 2008. RIVM. Melden van infectieziekten conform de wet publieke gezondheid. Bilthoven: RIVM, 2008.
6.
go back to reference CBS. Statistical Yearbook of the Netherlands 2004. Den Haag: CBS, 2004. CBS. Statistical Yearbook of the Netherlands 2004. Den Haag: CBS, 2004.
8.
go back to reference Bell BP, Negus S, Fiore AE, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007;26(2):116–22.CrossRefPubMed Bell BP, Negus S, Fiore AE, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007;26(2):116–22.CrossRefPubMed
9.
go back to reference Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007;357(17):1685–94.CrossRefPubMed Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007;357(17):1685–94.CrossRefPubMed
10.
go back to reference Lee C, Gong Y, Brok J, et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006(2): CD004790.PubMed Lee C, Gong Y, Brok J, et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006(2): CD004790.PubMed
11.
go back to reference Nothdurft HD, Zuckerman J, Stoffel M, et al. Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travellers. J Travel Med 2004;11:260–2.CrossRefPubMed Nothdurft HD, Zuckerman J, Stoffel M, et al. Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travellers. J Travel Med 2004;11:260–2.CrossRefPubMed
12.
go back to reference Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43(3):425–33.CrossRefPubMed Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43(3):425–33.CrossRefPubMed
13.
go back to reference Janssen HL, Zonneveld M van, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123–9.CrossRefPubMed Janssen HL, Zonneveld M van, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123–9.CrossRefPubMed
14.
go back to reference Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004;10(8):968–74.CrossRefPubMed Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004;10(8):968–74.CrossRefPubMed
Metagegevens
Titel
21 Hepatitis
Auteur
Dr. E.H. van de Lisdonk
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-7249-2_21